Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection

a multicenter study

on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Improving apheresis technology may lead to an efficient and safe peripheral blood stem cell (PBSC) collection. Recently, the Spectra Optia (Optia, Terumo BCT) was introduced as an automated apheresis instrument, but comparisons with other instruments have been few. This is the first randomized multicenter and crossover comparison of the Optia with the automated program of the established apheresis instrument, the Spectra (Spectra-Auto, Terumo BCT). STUDY DESIGN AND METHODS: A total of 233 apheresis procedures performed in 46 autologous patients and 108 allogeneic donors were investigated. Apheresis performed in the first day for all subjects using the Spectra-Auto (n = 79) and the Optia (n = 75) were evaluated as first-day analysis. Seventy-nine subjects, who required another session on the second day, underwent apheresis using the other instrument than the first-day instrument and were compared with each other in a paired crossover analysis. RESULTS: The two instruments processed similar volumes with comparable run times and volumes of acid-citrate-dextrose used. The volumes of collected products were greater in the Optia. Yields of mononuclear cells and CD34+ cells were not different, but collection efficiencies were higher in the Optia (p = 0.008 in CE1 of crossover analysis). Spectra-Auto–collected products contained more contaminating red blood cells (RBCs), whereas there was a trend of more contaminating platelets (PLTs) in the Optia-collected products. Slight reductions were noted in the RBC or PLT counts of subjects who underwent apheresis with the Spectra-Auto or the Optia, respectively. CONCLUSION: The Optia is safe and more efficient in the PBSC collection compared with the Spectra-Auto.

Original languageEnglish
Pages (from-to)2839-2847
Number of pages9
JournalTransfusion
Volume56
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1
Externally publishedYes

Fingerprint

Blood Component Removal
Multicenter Studies
Erythrocyte Count
Peripheral Blood Stem Cells
Platelet Count
Blood Platelets
Erythrocytes
Tissue Donors
Technology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy (2016). Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study. Transfusion, 56(11), 2839-2847. https://doi.org/10.1111/trf.13777

Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection : a multicenter study. / on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy.

In: Transfusion, Vol. 56, No. 11, 01.11.2016, p. 2839-2847.

Research output: Contribution to journalArticle

on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy 2016, 'Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study', Transfusion, vol. 56, no. 11, pp. 2839-2847. https://doi.org/10.1111/trf.13777
on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy. Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study. Transfusion. 2016 Nov 1;56(11):2839-2847. https://doi.org/10.1111/trf.13777
on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy. / Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection : a multicenter study. In: Transfusion. 2016 ; Vol. 56, No. 11. pp. 2839-2847.
@article{689c59d320f24b2e8936c3716d48d72a,
title = "Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study",
abstract = "BACKGROUND: Improving apheresis technology may lead to an efficient and safe peripheral blood stem cell (PBSC) collection. Recently, the Spectra Optia (Optia, Terumo BCT) was introduced as an automated apheresis instrument, but comparisons with other instruments have been few. This is the first randomized multicenter and crossover comparison of the Optia with the automated program of the established apheresis instrument, the Spectra (Spectra-Auto, Terumo BCT). STUDY DESIGN AND METHODS: A total of 233 apheresis procedures performed in 46 autologous patients and 108 allogeneic donors were investigated. Apheresis performed in the first day for all subjects using the Spectra-Auto (n = 79) and the Optia (n = 75) were evaluated as first-day analysis. Seventy-nine subjects, who required another session on the second day, underwent apheresis using the other instrument than the first-day instrument and were compared with each other in a paired crossover analysis. RESULTS: The two instruments processed similar volumes with comparable run times and volumes of acid-citrate-dextrose used. The volumes of collected products were greater in the Optia. Yields of mononuclear cells and CD34+ cells were not different, but collection efficiencies were higher in the Optia (p = 0.008 in CE1 of crossover analysis). Spectra-Auto–collected products contained more contaminating red blood cells (RBCs), whereas there was a trend of more contaminating platelets (PLTs) in the Optia-collected products. Slight reductions were noted in the RBC or PLT counts of subjects who underwent apheresis with the Spectra-Auto or the Optia, respectively. CONCLUSION: The Optia is safe and more efficient in the PBSC collection compared with the Spectra-Auto.",
author = "{on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy} and Kazuhiko Ikeda and Keiji Minakawa and Kazuo Muroi and Fujiwara, {Shin Ichiro} and Minami Yamada-Fujiwara and Yoshihiro Fujimori and Ryuji Tanosaki and Hitoshi Ohto",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/trf.13777",
language = "English",
volume = "56",
pages = "2839--2847",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection

T2 - a multicenter study

AU - on behalf of the Study Group for Peripheral Blood Stem Cell Collection, Cell Therapy Committee, The Japan Society of Transfusion Medicine and Cell Therapy

AU - Ikeda, Kazuhiko

AU - Minakawa, Keiji

AU - Muroi, Kazuo

AU - Fujiwara, Shin Ichiro

AU - Yamada-Fujiwara, Minami

AU - Fujimori, Yoshihiro

AU - Tanosaki, Ryuji

AU - Ohto, Hitoshi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - BACKGROUND: Improving apheresis technology may lead to an efficient and safe peripheral blood stem cell (PBSC) collection. Recently, the Spectra Optia (Optia, Terumo BCT) was introduced as an automated apheresis instrument, but comparisons with other instruments have been few. This is the first randomized multicenter and crossover comparison of the Optia with the automated program of the established apheresis instrument, the Spectra (Spectra-Auto, Terumo BCT). STUDY DESIGN AND METHODS: A total of 233 apheresis procedures performed in 46 autologous patients and 108 allogeneic donors were investigated. Apheresis performed in the first day for all subjects using the Spectra-Auto (n = 79) and the Optia (n = 75) were evaluated as first-day analysis. Seventy-nine subjects, who required another session on the second day, underwent apheresis using the other instrument than the first-day instrument and were compared with each other in a paired crossover analysis. RESULTS: The two instruments processed similar volumes with comparable run times and volumes of acid-citrate-dextrose used. The volumes of collected products were greater in the Optia. Yields of mononuclear cells and CD34+ cells were not different, but collection efficiencies were higher in the Optia (p = 0.008 in CE1 of crossover analysis). Spectra-Auto–collected products contained more contaminating red blood cells (RBCs), whereas there was a trend of more contaminating platelets (PLTs) in the Optia-collected products. Slight reductions were noted in the RBC or PLT counts of subjects who underwent apheresis with the Spectra-Auto or the Optia, respectively. CONCLUSION: The Optia is safe and more efficient in the PBSC collection compared with the Spectra-Auto.

AB - BACKGROUND: Improving apheresis technology may lead to an efficient and safe peripheral blood stem cell (PBSC) collection. Recently, the Spectra Optia (Optia, Terumo BCT) was introduced as an automated apheresis instrument, but comparisons with other instruments have been few. This is the first randomized multicenter and crossover comparison of the Optia with the automated program of the established apheresis instrument, the Spectra (Spectra-Auto, Terumo BCT). STUDY DESIGN AND METHODS: A total of 233 apheresis procedures performed in 46 autologous patients and 108 allogeneic donors were investigated. Apheresis performed in the first day for all subjects using the Spectra-Auto (n = 79) and the Optia (n = 75) were evaluated as first-day analysis. Seventy-nine subjects, who required another session on the second day, underwent apheresis using the other instrument than the first-day instrument and were compared with each other in a paired crossover analysis. RESULTS: The two instruments processed similar volumes with comparable run times and volumes of acid-citrate-dextrose used. The volumes of collected products were greater in the Optia. Yields of mononuclear cells and CD34+ cells were not different, but collection efficiencies were higher in the Optia (p = 0.008 in CE1 of crossover analysis). Spectra-Auto–collected products contained more contaminating red blood cells (RBCs), whereas there was a trend of more contaminating platelets (PLTs) in the Optia-collected products. Slight reductions were noted in the RBC or PLT counts of subjects who underwent apheresis with the Spectra-Auto or the Optia, respectively. CONCLUSION: The Optia is safe and more efficient in the PBSC collection compared with the Spectra-Auto.

UR - http://www.scopus.com/inward/record.url?scp=84992111924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992111924&partnerID=8YFLogxK

U2 - 10.1111/trf.13777

DO - 10.1111/trf.13777

M3 - Article

VL - 56

SP - 2839

EP - 2847

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11

ER -